Limited utility of fluorescencein situhybridization for common abnormalities of myelodysplastic syndrome at first presentation and follow-up of myeloid neoplasms-Reference-Cited by-同舟云学术

Limited utility of fluorescencein situhybridization for common abnormalities of myelodysplastic syndrome at first presentation and follow-up of myeloid neoplasms

Published:2013-08-28 Issue:3 Volume:55 Page:601-605
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Seegmiller Adam C.,Wasserman Allison,Kim Annette S.,Kressin Megan K.,Marx Edward R.,Zutter Mary M.,Mosse Claudio A.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.801470

Reference21 articles.

1. Revised International Prognostic Scoring System for Myelodysplastic Syndromes

2. Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies

3. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Section E6.1–6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes;Genetics in Medicine;2024-04

2. Molecular Techniques and Gene Mutations in Myelodysplastic Syndromes;Clinics in Laboratory Medicine;2023-12

3. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia;Blood;2022-11-24

4. The utility of fluorescence in situ hybridization testing in patients clinically suspected of myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm overlap is limited in the absence of significant morphological dysplasia;International Journal of Laboratory Hematology;2020-08-27

5. How I Diagnose Low-Grade Myelodysplastic Syndromes;American Journal of Clinical Pathology;2020-05-27